- /
- Supported exchanges
- / BE
- / HIUC.BE
CN TAIPING INSU (HIUC BE) stock market data APIs
CN TAIPING INSU Financial Data Overview
There is no Profile data available for HIUC.BE.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get CN TAIPING INSU data using free add-ons & libraries
Get CN TAIPING INSU Fundamental Data
CN TAIPING INSU Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CN TAIPING INSU News
New
AM Best Affirms Credit Ratings of China Taiping Insurance (Singapore) Pte. Ltd.
SINGAPORE, October 17, 2025--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a" (Excellent) of China Taiping Insurance (...
Is China Taiping Insurance (SEHK:966) Trading Below Its True Value? A Closer Look at Current Valuation
China Taiping Insurance Holdings (SEHK:966) has caught the eye of investors recently, though not because of any dramatic news or headline-grabbing developments. Sometimes, price moves without a clear ...
AM Best Affirms Credit Ratings of Taiping Reinsurance Company Limited and Its Subsidiary
HONG KONG, September 19, 2025--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings of "a" (Excellent) of Taiping Reinsurance Co...
AI Drug Firm METiS Considering $200 Million Hong Kong IPO, Sources Say
(Bloomberg) -- Artificial intelligence-driven drug firm METiS Pharmaceuticals is considering an initial public offering in Hong Kong to raise as much as $200 million, according to people familiar with...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.